These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32783372)

  • 21. Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review.
    Xie W; Hu N; Cao L
    Front Immunol; 2021; 12():790051. PubMed ID: 34956221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies.
    Matsumoto A; Nakashima C; Kimura S; Sueoka E; Aragane N
    BMC Cancer; 2021 May; 21(1):584. PubMed ID: 34022841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to pembrolizumab in a patient with primary lung adenocarcinoma originated from indium lung.
    Sekine Y; Ichimura H; Ueda S; Kobayashi K; Nawa T; Amata A; Chonan T; Sakata A; Komatsu Y; Sato Y
    BMC Pulm Med; 2021 Mar; 21(1):107. PubMed ID: 33789640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.
    Shionoya Y; Hirohashi Y; Takahashi H; Hashimoto M; Nishiyama K; Takakuwa Y; Nakatsugawa M; Kubo T; Kanaseki T; Tsukahara T; Torigoe T
    Anticancer Res; 2021 Jul; 41(7):3699-3706. PubMed ID: 34230169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.
    Byeon S; Cho JH; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Med; 2020 Apr; 9(7):2352-2362. PubMed ID: 32027780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing "wax-and-wane" transformation.
    Takagi Y; Nakahara Y; Hosomi Y; Hishima T
    BMC Cancer; 2013 Nov; 13():529. PubMed ID: 24195468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary pleomorphic carcinoma in an elderly patient treated with pembrolizumab shows a marked response.
    Yamasaki M; Matsumoto Y; Nakamoto K; Hattori N
    J Cancer Res Ther; 2021; 17(6):1580-1582. PubMed ID: 34916402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
    Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
    J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synchronous primary lung cancers: a multidisciplinary approach in diagnosis.
    Kontic M; Stevic R; Stojsic J; Jekic B; Bunjevacki V
    Tumori; 2011; 97(4):e16-9. PubMed ID: 21989450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma.
    Horibe R; Hatakeyama T; Ishikawa T; Sawai T; Hashimoto M; Domen H; Takakuwa Y; Satoh M; Nishiyama K
    Intern Med; 2022 Feb; 61(3):401-405. PubMed ID: 34393158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.
    Tang Y; Li Y; Zhang L; Tong G; Ou Z; Wang Z; Zhang H; Qiao G
    Thorac Cancer; 2020 Apr; 11(4):1094-1098. PubMed ID: 32077636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
    Egawa T; Masuzawa K; Nakayama S; Maeda I; Tsunematsu S; Suzuki Y; Suzuki Y
    Intern Med; 2021 Oct; 60(20):3273-3277. PubMed ID: 33840693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Method for discriminating synchronous multiple lung cancers of the same histological type: miRNA expression analysis.
    Zhou X; Tian L; Fan J; Lai Y; Li S; Che G; Huang J
    Medicine (Baltimore); 2016 Aug; 95(31):e4478. PubMed ID: 27495091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.
    Nabeshima S; Yamasaki M; Matsumoto N; Takaki S; Nishi Y; Kawamoto K; Taniwaki M; Ohashi N; Hattori N
    Cancer Treat Res Commun; 2021; 26():100270. PubMed ID: 33338849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sarcoid-like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab.
    Takamori S; Furubayashi N; Taguchi K; Matsubara T; Fujishita T; Ito K; Yamaguchi M; Toyozawa R; Seto T; Negishi T; Nakamura M; Okamoto T
    Thorac Cancer; 2021 Jul; 12(14):2122-2125. PubMed ID: 34002950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
    Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
    Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
    Takamori S; Komiya T; Powell E
    Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report.
    Hirai T; Inomata M; Minatoyama S; Hashizume M; Takata N; Hayashi K; Seto Z; Tokui K; Taka C; Okazawa S; Kambara K; Imanishi S; Miwa T; Hayashi R; Tanaka S; Noguchi A; Sato T
    In Vivo; 2024; 38(3):1509-1511. PubMed ID: 38688637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
    Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
    Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
    Koda K; Toyoshima M; Yazawa S; Fukada A; Sugimura H; Suda T
    Thorac Cancer; 2021 Jun; 12(11):1765-1769. PubMed ID: 33939308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.